Valeant Pharma (VRX) Reports Q4 EPS of $2.15; Reaffirms Outlook

February 27, 2014 6:02 AM

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $2.15 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found